These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22644939)

  • 1. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.
    Williams HD; Sassene P; Kleberg K; Bakala-N'Goma JC; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Carrière F; Müllertz A; Porter CJ; Pouton CW
    J Pharm Sci; 2012 Sep; 101(9):3360-80. PubMed ID: 22644939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
    Williams HD; Anby MU; Sassene P; Kleberg K; Bakala-N'Goma JC; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Carrière F; Müllertz A; Pouton CW; Porter CJ
    Mol Pharm; 2012 Nov; 9(11):3286-300. PubMed ID: 23030411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
    Williams HD; Sassene P; Kleberg K; Calderone M; Igonin A; Jule E; Vertommen J; Blundell R; Benameur H; Müllertz A; Porter CJ; Pouton CW;
    J Pharm Sci; 2014 Aug; 103(8):2441-55. PubMed ID: 24985238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
    Devraj R; Williams HD; Warren DB; Mohsin K; Porter CJ; Pouton CW
    Eur J Pharm Sci; 2013 Jul; 49(4):748-60. PubMed ID: 23684915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
    Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
    Anby MU; Nguyen TH; Yeap YY; Feeney OM; Williams HD; Benameur H; Pouton CW; Porter CJ
    Mol Pharm; 2014 Nov; 11(11):4069-83. PubMed ID: 25265395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simplified method to screen for in-vivo performance of oral lipid formulations.
    Kilic M; Dressman J
    J Pharm Pharmacol; 2014 May; 66(5):615-23. PubMed ID: 24313318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a high-throughput in vitro intestinal lipolysis model for rapid screening of lipid-based drug delivery systems.
    Mosgaard MD; Sassene P; Mu H; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2015 Aug; 94():493-500. PubMed ID: 26159837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.
    Williams HD; Sassene P; Kleberg K; Calderone M; Igonin A; Jule E; Vertommen J; Blundell R; Benameur H; Müllertz A; Pouton CW; Porter CJ;
    Pharm Res; 2013 Dec; 30(12):3059-76. PubMed ID: 23661145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability.
    Tanaka Y; Nguyen TH; Suys EJA; Porter CJH
    Mol Pharm; 2021 Apr; 18(4):1768-1778. PubMed ID: 33729806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
    Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS
    J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro.
    Keemink J; Mårtensson E; Bergström CAS
    Mol Pharm; 2019 Mar; 16(3):921-930. PubMed ID: 30628771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM; Williams HD; Pouton CW; Porter CJ
    J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems.
    Anby MU; Williams HD; McIntosh M; Benameur H; Edwards GA; Pouton CW; Porter CJ
    Mol Pharm; 2012 Jul; 9(7):2063-79. PubMed ID: 22656917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid determination of drug solubilization versus supersaturation in natural and digested lipids.
    Gautschi N; Bergström CA; Kuentz M
    Int J Pharm; 2016 Nov; 513(1-2):164-174. PubMed ID: 27609663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-based formulations solidified via adsorption onto the mesoporous carrier Neusilin® US2: effect of drug type and formulation composition on in vitro pharmaceutical performance.
    Williams HD; Van Speybroeck M; Augustijns P; Porter CJ
    J Pharm Sci; 2014 Jun; 103(6):1734-46. PubMed ID: 24740767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 6: effects of varying pancreatin and calcium levels.
    Sassene P; Kleberg K; Williams HD; Bakala-N'Goma JC; Carrière F; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Porter CJ; Pouton CW; Müllertz A
    AAPS J; 2014 Nov; 16(6):1344-57. PubMed ID: 25274609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 50years of oral lipid-based formulations: Provenance, progress and future perspectives.
    Feeney OM; Crum MF; McEvoy CL; Trevaskis NL; Williams HD; Pouton CW; Charman WN; Bergström CAS; Porter CJH
    Adv Drug Deliv Rev; 2016 Jun; 101():167-194. PubMed ID: 27089810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.
    Crum MF; Trevaskis NL; Williams HD; Pouton CW; Porter CJ
    Pharm Res; 2016 Apr; 33(4):970-82. PubMed ID: 26703975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase.
    Bakala-N'Goma JC; Williams HD; Sassene PJ; Kleberg K; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Müllertz A; Pouton CW; Porter CJ; Carrière F
    Pharm Res; 2015 Apr; 32(4):1279-87. PubMed ID: 25288015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.